Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Development and application of gene therapy technologies].

Keiya Ozawa1

  • 1Division of Hematology, Department of Medicine, Jichi Medical School, 3311- 1 Yakushiji, Minamikawachi-machi Kawachi-gun, Tochigi 329-0498, Japan. kozawa@ms2.jichi.ac.jp

Uirusu
|September 29, 2004
PubMed
Summary

Hematopoietic stem cell gene therapy shows promise but faces challenges like leukemia risk due to retroviral vectors. Research is ongoing to improve vector safety and develop new gene therapy technologies for various diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Soluble PD-L1-secreting umbilical cord-derived mesenchymal stromal cells transiently attenuate established xenogeneic T cell activation in vivo.

Scientific reports·2026
Same author

Trichostatin A Sensitizes Tumor Cells to Apoptosis Induced by Soluble Trimeric TRAIL-Expressing Human Mesenchymal Stromal Cells.

Cancer science·2025
Same author

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia.

Blood advances·2025
Same author

Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.

British journal of haematology·2025
Same author

Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials.

Annals of hematology·2025
Same author

BCMA-CAR Therapy for Multiple Myeloma in NOG Mice Prevents the Progression of Anemia and Bone Lesions.

Human gene therapy·2025

Area of Science:

  • Gene Therapy
  • Molecular Biology
  • Oncology

Context:

  • Hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency (X-SCID) achieved success but led to leukemia in some patients.
  • Retroviral vector integration caused insertional mutagenesis, activating the LMO 2 gene and contributing to leukemogenesis.

Purpose:

  • To address safety concerns in gene therapy, specifically retroviral vector-mediated gene transfer.
  • To improve the safety of retroviral vectors and develop site-specific integration methods for transgenes.
  • To explore alternative vectors like Adeno-Associated Virus (AAV) for safer gene delivery.

Summary:

  • The study highlights the need for safer gene therapy vectors and integration techniques following leukemia development in X-SCID patients treated with retroviral vectors.

Related Experiment Videos

  • Development of technologies like selective amplifier genes (SAGs) is crucial for enhancing therapeutic efficacy in hematopoietic stem cell gene therapy.
  • Adeno-Associated Virus (AAV) vectors show promise for gene transfer into various tissues, with applications in diseases like Parkinson's and in regeneration medicine.

    • Impact:

    • Advances in gene therapy vector safety and integration methods are critical for successful clinical applications.
    • Improved gene therapy approaches can expand treatment options for genetic disorders and complex diseases.
    • Further basic research is essential for the advancement of gene therapy and regenerative medicine.